In our study, patients with high-grade glioma had the following mutational frequencies according to the tumor variety: glioblastoma (GBwt-IDH), in which mutations in the TERT promoter (13/22 Patients), and EGFR promoter (5/22 Patients). This evidence concerns the gene IDH1 and glioblastoma.